Cell-based vaccines can be derived from autologous or allogeneic human cancer cell lines or tumor lysates, either loaded on dendritic cells or administered in adjuvants to promote dendritic cell activation in order to stimulate specific CD8+ and CD4+ T cell responses [7]. The gene discussed is CD8A; the disease is neoplasm.